Wholesale Medicine Grade Raw Materials Dienogest Powder CAS 65928-58-7 Dienogestrel /Dienogest

• Customization: Available
• CAS No.: 65928-58-7
• Formula: C20h25no2
• Model NO.: 65928-58-7
• EINECS: 639-448-2
• Type: Pharmaceutical Intermediates
• Appearance: Powder
• Quality: Refined
• Product Name: Dienogestrel
• Grade Standard: Pharm Grade
• Function: Healthcare
• Shelf Life: 2 Years
• Certificate: GMP ISO USP Bp
• Storage: Cool Dry Place
• Transport Package: Dry and Cool
• Specification: 1kg/Bag, 25kg/Drum
• Trademark: Gina
• Origin: Shaanxi, China
• Production Capacity: 100000 Kilogram/ Month

Product Description

What is Dienogest ?

Dienogest is a progestin, or a synthetic progestogen, of the 19-nortestosterone group. It is available incombination with estradiol valerate (as Natazia, Qlaira) or ethinylestradiol (as Valette) for use as an oral contraceptive, and by itself (as Visanne, Dinagest) for the treatment of endometriosis in Europe, Australia, and Japan. Although available in combination with estrogen as a contraceptive in the United States, dienogest is not available in this country by itself. In addition to its progestogenic effects, dienogest has antiandrogenic activity, and as a result can improve androgenic symptoms such as acne.
 

Product Name	Wholesale Medicine Grade Raw Materials Dienogest Powder CAS 65928-58-7 Dienogestrel /Dienogest
Appearance	White powder
Molecular formula	C20H25NO2
Molecular Weight	311.43
Keywords	Dienogest Powder;Dienogest Dienogestrel;Dienogest CAS 65928-58-7
Shelf Life	24 months when properly stored
Storage	Keep in a cool, dry, dark location

 

Endometriosis is a chronic, estrogen-dependent disease that affects approximately 10% of women of reproductive age, with a peak incidence in the age range of 25-30 years.1-3 Endometriosis is characterized by the formation of endometriotic lesions outside the uterus, including the ovaries and other pelvic structures. These lesions cause a chronic, inflammatory reaction, which can lead to the formation of scar tissue and adhesions.4 Women with endometriosis frequently experience symptoms of dysmenorrhea, premenstrual pain, dyspareunia, and chronic fatigue.5 Endometriosis can also interfere with functioning of the bowel or bladder, depending on the site where endometriotic lesions develop. Up to 50% of women with endometriosis experience infertility.6 However, the clinical presentations of endometriosis can vary widely, and many affected women are asymptomatic.7 No clear relationship exists between the extent of endometriotic lesions and a woman's symptoms.

Application of Dienogest 

(1). Dienogest has moderate affinity for the progesterone receptor in human uterus tissue, in vitro, about 10% that of progesterone.
(2). Inhibition of ovulation
The minimum effective dose of oral dienogest required to inhibit ovulation is 1 mg/day. The inhibition of ovulation by dienogest occurs mainly via peripheral action as opposed to central action on gonadotrophin secretion. Oral treatment of dienogest 2 mg/day in cyclical women reduced serum progesterone levels to anovulatory levels, however serum levels of lutenising hormone and follicle-stimulating hormone are not significantly altered.